Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer

Background The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2020-12, Vol.23 (4), p.705-713
Main Authors: Du, Meijun, Tian, Yijun, Tan, Winston, Wang, Liewei, Wang, Liguo, Kilari, Deepak, Huang, Chiang-Ching, Wang, Liang, Kohli, Manish
Format: Article
Language:English
Subjects:
45
631/67/589/466
692/53/2422
692/53/2423
Acetic acid
Amplification
Analysis
Biomarkers
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Care and treatment
Castration
Chemotherapy
Copy number
Corticosteroids
Deoxyribonucleic acid
Development and progression
DNA
Genes
Genomes
Genomics
Medical prognosis
Metastases
Metastasis
Nkx3.1 protein
Plasma
Prednisone
Prognosis
Prostate cancer
Regression analysis
Resistance factors
Risk analysis
Risk factors
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive and prognostic biomarkers for metastatic castration-resistant prostate cancer (mCRPC). Methods Serial plasma specimens were prospectively collected from 88 chemotherapy-naive mCRPC patients before and after 12 weeks of AA/P treatment. Sequencing-based CNA analyses were performed on 174 specimens. We evaluated CNA-associated 12-week responses for primary resistance, time to treatment change (TTTC) for secondary resistance, and overall survival for prognosis ( P  
ISSN:1365-7852
1476-5608
DOI:10.1038/s41391-020-0224-4